AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A method for detecting anaplastic lymphoma kinase (ALK) ~~ALK~~ tyrosine kinase activity, which comprises the following steps: i) incubating the ALK protein or a functional derivative thereof with a peptide substrate ~~selected from~~ comprising SEQ ID NO: 1 ~~N. 1 or 2~~ in conditions suitable for phosphorylation of the peptide; and ii) detecting the phosphorylated peptide, wherein the phosphorylated peptide correlates to the tyrosine kinase activity.

2. (canceled)

3. (currently amended) ~~A~~ The method according to claim 1, wherein purified ALK protein or an ALK-containing preparation is used.

4. (currently amended) ~~A~~ The method according to claim 3, wherein said preparation is a cell lysate.

5. (currently amended) ~~A~~ The method according to claim 1, wherein said ALK functional derivative comprises ~~contains the entire catalytic domain of ALK spanning~~ residues 1116-1392 of SEQ ID NO: 6 ~~ALK sequence~~.

6. (currently amended) ~~A~~ The method according to claim 5, wherein said ALK functional derivative is a fragment of ALK protein extending from residue Leu^{1073} to Ala^{1459} ~~Leu1o to Alla'~~.

7. (currently amended) ~~A~~ The method according to claim 6, which comprises the steps of : a) adhering ~~a peptide of SEQ ID N. 1 or 2~~ the peptide comprising SEQ ID NO: 1 to a solid phase; b) incubating the solid phase with said ALK fragment in conditions suitable for tyrosine phosphorylation; c) washing the solid phase; d) incubating the solid phase with an anti-phosphotyrosine antibody (primary antibody) in conditions suitable for antigen-antibody binding; e) washing the solid phase; f) incubating the solid phase with an enzyme-conjugated antibody (secondary antibody) recognizing the primary antibody in conditions suitable for the binding of primary and secondary antibodies, so that a ternary immune complex is formed; g) washing the solid phase ; h) measuring the enzymatic activity of

the immune complex wherein the measured activity is proportional to ~~the~~ an amount of tyrosine-phosphorylation.

8. (currently amended) ~~A~~ The method according to claim 7, wherein the enzyme conjugated to the antibody is Horse-Radish peroxidase.

9. (currently amended) ~~A~~ The method according to claim 7, wherein the enzymatic activity is detected by colorimetric reaction.

10. (currently amended) A method ~~according to claim 1,~~ for the identification of compounds that modulate ALK tyrosine-kinase activity, comprising the method according to claim 1, wherein step (i) further comprises incubating ALK protein or a functional derivative thereof with the peptide substrate comprising SEQ ID NO: 1 in the presence of a candidate compound (a) in conditions suitable for phosphorylation of the peptide.

11. (canceled)

12. (currently amended) ~~A~~ The method according to claim 10, wherein the ALK-modulating activity of the candidate compound is compared to that of a reference compound which is assayed under the same conditions as the candidate compound.

13. (currently amended) ~~A~~ The method according to claim 12, wherein the reference compound is staurosporine.

14. (currently amended) ~~A~~ The method according to claim 12, wherein the reference compound is a staurosporine derivative of general formula (I):



wherein Rl and R2, independently of one another, are selected from halogen, preferably chlorine, phenyl or C1-C3 alkyl optionally substituted with one or more halogens; R3 is hydroxyl; R4 is hydroxyl or hydroxymethyl; R5 is Cl-C3 alkyl, C1-C3 alkyl-halo substituted or C1-C3 alkyl-benzyl ~~optionally halo-substituted, or benzyl~~.

15. (currently amended) A peptide useful as ALK substrate comprising SEQ ID NO: 1 ~~selected from SEQ ID N. 1 or 2~~.

16. (currently amended) ~~A~~ The peptide according to claim 15, ~~which~~ wherein the peptide is SEQ ID NO: 1 ~~N. 1~~.

17. (canceled)

18. (currently amended) ~~The use of a compound of formula (1), as per claim 14, for the preparation of a~~ A medicament for the treatment of ALK-related tumors, ~~especially~~ anaplastic large cell lymphomas, and non-Hodgkin lymphomas, comprising a staurosporine derivative of general formula (I)



wherein Rl and R2, independently of one another, are selected from halogen, preferably chlorine, phenyl or C1-C3 alkyl

optionally substituted with one or more halogens; R3 is hydroxyl; R4 is hydroxyl or hydroxymethyl; R5 is C1-C3 alkyl, C1-C3 alkyl-halo substituted or C1-C3 alkyl-benzyl.

19. (currently amended) A kit for detecting ALK tyrosine-kinase activity utilizing the method according to claim 1, which comprises a peptide comprising SEQ ID NO: 1 ~~of SEQ ID N: 1 or 2~~ and an anti-phosphotyrosine antibody.

20. (currently amended) ~~A~~ The kit according to claim 19, further comprising ~~containing an additional component selected from reagents for colorimetric reactions,~~ buffers, diluents, detergents, stabilizers, or staurosporine or a derivative thereof.